A Prospective, Randomized Comparison of Paclitaxel- eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.

Slides:



Advertisements
Similar presentations
SPIRIT IV A Prospective, Randomized Trial Comparing an Everolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease.
Advertisements

A Prospective, Randomized Comparison of Paclitaxel-eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction.
Stone p2203/Abstract/ Conclusions
Comparison of AngioJET Rheolytic Thrombectomy Before Direct Infarct Artery STENTing in Patients with Acute Myocardial Infarction: the JETSTENT trial David.
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
University Medical Center Groningen Thrombus aspiration during primary PCI FZ Thrombus Aspiration during Percutaneous coronary intervention in Acute.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
Presentation at a Non PCI Facility Requiring Transfer Does NOT Worsen Long-term Prognosis in Patients With STEMI Undergoing Primary Angioplasty. The HORIZONS-AMI.
HORIZONS AMI Trial H armonizing O utcomes with R evascular IZ ati ON and S tents In A cute M ycoardial I nfarction H armonizing O utcomes with R evascular.
TCT 2009 Stent Thrombosis Following Primary PCI in STEMI: Predictors, Clinical Impact and Preventive Strategies from the Horizons AMI Trial George D. Dangas,
A Prospective, Randomized Comparison of Bivalirudin vs. Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Primary Angioplasty in Acute Myocardial Infarction.
Welcome Ask The Experts March 24-27, 2007 New Orleans, LA.
Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction The HORIZONS-SWITCH Analysis HORIZONS AMI Dangas G, et al.
比伐卢定在 STEMI 中的应用价值 王乐丰 首都医科大学附属北京朝阳医院心脏中心. Goals of STEMI PCI Establish reperfusion of IRA ASAP Limit complications Limit costs Achieve excellent long.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
New Horizons for Patients with ST-Elevation Myocardial Infarction Gregg W. Stone MD Columbia University Medical Center Cardiovascular Research Foundation.
Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) Trial Presented at The American College of Cardiology.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
Harmonizing Outcomes with RevascularIZatiON and Stents (HORIZONS) Trial HORIZONS Trial.
A Prospective, Randomized Evaluation of Supersaturated Oxygen Therapy After Percutaneous Coronary Intervention in Acute Anterior Myocardial Infarction.
Dr Jonathan Day Senior Director Global Medical The Medicines Company Bivalirudin For patients with STEMI undergoing primary PCI.
ARNO TRIAL (Antithrombotic Regimens aNd Outcome) A RANDOMIZED TRIAL COMPARING BIVALIRUDIN WITH UNFRACTIONED HEPARIN IN PATIENTS UNDERGOING ELECTIVE PCI.
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Trial Vignettes 1-3 Mark Mason Harefield Hospital Royal Brompton and Harefield NHS Trust.
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Gregg W. Stone MD for the ACUITY Investigators Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Gender Differences in Long-Term Outcomes Following PCI of Patients with Non-ST Elevation ACS: Results from the ACUITY Trial Alexandra J. Lansky on behalf.
Gregg W. Stone MD for the ACUITY Investigators A Prospective, Randomized Trial of Bivalirudin in Acute Coronary Syndromes Final One-Year Results from the.
Impact Of Diabetes Mellitus On The Safety And Effectiveness Of Bivalirudin In Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty:
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Duration Safety and Efficacy of Bivalirudin in patients undergoing PCI: The impact of duration of infusion in ACUITY trial Dr. David Cox Lehigh Valley.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at The American College.
Everolimus-eluting Bioresorbable Vascular Scaffolds in Patients with Coronary Artery Disease: ABSORB III Trial 2-Year Results Stephen G. Ellis, MD,
Disclosures Runlin Gao has received a research grant
Runlin Gao, M.D. On behalf of ABSORB China Investigators
Gregg W. Stone MD for the ACUITY Investigators
For the HORIZONS-AMI Investigators
Damian Gimpel Waikato Cardiothoracic Unit Journal Club
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
DES Should be Used as the Default Stent in ACS!
Predictors of Acute, Subacute and Late Stent Thrombosis After Acute MI Primary Angioplasty in the Horizons AMI Trial George D. Dangas, Alexandra J. Lansky,
For the HORIZONS AMI Investigators
The American College of Cardiology Presented by Dr. Maurits T. Dirksen
The HORIZONS-AMI Trial
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
American Heart Association Presented by Dr. Julinda Mehilli
Impact of Platelet Reactivity Following Clopidogrel Administration
STENT THROMBISIS Insights on Outcomes and Impact of DUAL ANTIPLATELET THERAPY Permanent Discontinuation SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE.
Gregg W. Stone, MD Columbia University Medical Center
Presented at TCT 2006.
Impact of Diabetes Mellitus on Long-term Outcomes in the
Maintenance of Long-Term Clinical Benefit with
OASIS-5: Study Design Randomize N=20,078 Enoxaparin (N=10,021)
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Infarct Size after Primary Angioplasty Patients With Bivalirudin
Comparison of Everolimus-Eluting and Paclitaxel-Eluting Stents: First Report of the Five-Year Clinical Outcomes from.
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

A Prospective, Randomized Comparison of Paclitaxel- eluting TAXUS Stents vs. Bare Metal Stents During Primary Angioplasty in Acute Myocardial Infarction – One Year Results – HORIZONS AMI Trial Gregg W. Stone MD For the HORIZONS-AMI Investigators, TCT 2008

Background ● No consensus exists regarding the safety and efficacy of drug- eluting stents in pts with STEMI undergoing primary PCI –TLR and restenosis rates tend to be lower in STEMI vs. elective PCI patients because of less plaque burden and non viable myocardium –The safety of implanting DES in ruptured plaques with thrombus has been questioned ● Outcomes from registry studies of DES vs. BMS in STEMI have been conflicting, and no large-scale randomized trials have been performed Stone GW. TCT 2008.

CABG – Primary PCI – Medical Rx Aspirin, thienopyridine R 1:1 3,000 pts eligible for stent randomization R 3:1 Paclitaxel-eluting TAXUS stentBare metal EXPRESS stent HORIZONS AMI Trial Design Harmonizing Outcomes with Revascularization and Stents in AMI 3 UFH + GP IIb/IIIa inhibitor (abciximab or eptifibatide) Bivalirudin monotherapy (± provisional GP IIb/IIIa) 3,602 pts with STEMI with symptom onset ≤12 hours Emergent angiography, followed by triage to… Clinical FU at 30 days, 6 months, 1 year, and then yearly through 5 years; angio FU at 13 months Clinical FU at 30 days, 6 months, 1 year, and then yearly through 5 years; angio FU at 13 months Stone GW. NEJM 2008;358:

Stent Randomization Hypotheses ● In patients with STEMI undergoing primary PCI, the use of paclitaxel-eluting TAXUS stents rather than bare metal EXPRESS stents will be: –Efficacious, as evidenced by reduced rates of ischemia-driven target lesion revascularization at 1-year and angiographic binary restenosis at 13 months; and –Safe, with non-inferior rates of the composite measure of death, reinfarction, stent thrombosis or stroke at 1-year Stone GW. TCT 2008.

Clinical Inclusion Criteria ● STEMI >20 mins and <12 hours in duration –ST-segment elevation of  1 mm in  2 contiguous leads; or –Presumably new left bundle branch block; or –True posterior MI with ST depression of  1 mm in  2 contiguous anterior leads –Patients with cardiogenic shock, left main disease, etc., were not excluded ● Age ≥18 years ● Written, informed consent Stone GW. NEJM 2008;358:

Principal Clinical Exclusion Criteria ● Contraindication to any of the study medications ● Prior administration of thrombolytic therapy, bivalirudin, GP IIb/IIIa inhibitors, LMWH or fondaparinux for the present admission (prior UFH allowed) ● Current use of coumadin ● History of bleeding diathesis or known coagulopathy (including HIT), or will refuse blood transfusions ● History of intracerebral mass, aneurysm, AVM, or hemorrhagic stroke; stroke or TIA within 6 months or any permanent neurologic deficit; GI or GU bleed within 2 months, or major surgery within 6 weeks; recent or known platelet count <100,000 cells/mm 3 or hgb <10 g/dL ● Planned elective surgical procedure that would necessitate interruption of thienopyridines during the first 6 months post enrollment Stone GW. NEJM 2008;358:

Angiographic Inclusion Criteria ● The presence of least 1 acute infarct artery target vessel* in which: –a) ALL significant lesions are eligible for stenting with study stents, and –b) ALL such lesions have a visually estimated reference diameter ≥2.25 mm and ≤4.0 mm ● Expected ability to deliver the stent(s) to all culprit lesions (absence of excessive proximal tortuosity or severe calcification) ● Expected ability to fully expand the stent(s) at all culprit lesions (absence of marked calcification) *Arteries containing multiple lesions may be randomized if all lesions are study stent eligible; multiple vessels may be randomized if all lesions in each vessel are study stent eligible Stone GW. TCT 2008.

Angiographic Exclusion Criteria ● Bifurcation lesion definitely requiring implantation of stents in both the main vessel + side branch ● Infarct related artery is an unprotected left main ● >100 mm of study stent length anticipated ● Infarction due to stent thrombosis, or infarct lesion at the site of a previously implanted stent ● High likelihood of CABG within 30 days anticipated Stone GW. TCT 2008.

Study Medications (i) ● Unfractionated heparin –60 U/kg IV*; subsequent boluses titrated by nomogram to ACT secs; terminated at procedure end unless prolonged antithrombin needed ● Bivalirudin –Bolus 0.75 mg/kg IV**, infusion 1.75 mg/kg/h, not titrated to ACT; terminated at procedure end unless prolonged antithrombin needed (0.25 mg/kg/hr infusion) ● Glycoprotein IIb/IIIa inhibitors –Routine use in UFH arm; recommended only for giant thrombus or refractory no reflow in bivalirudin arm –Abciximab or double bolus eptifibatide as per investigator discretion – dosing per FDA label, renal adjusted; continued for 12  (abciximab) or  (eptifibatide) * If pre randomization UFH administered, ACT is checked first ** If pre randomization UFH administered, started 30’ after last bolus Stone GW. NEJM 2008;358:

Study Medications (ii) ● Aspirin –324 mg chewed non enteric coated or 500 mg IV in the ER, followed by mg/day in-hospital and mg/day as out patient indefinitely ● Thienopyridines –Clopidogrel 300 mg or 600 mg loading dose (per investigator discretion) in the ER followed by 75 mg PO QD for at least 6 months (1 year or longer recommended) – Ticlopidine load + daily dose permissible if clopidogrel is unavailable or patient is allergic ● Other –Beta blockers: IV pre procedure followed by PO QD in the absence of contraindications; ACE inhibitors for HTN, CHF or LVEF 100 mg/dl Stone GW. NEJM 2008;358:

2 Primary Stent Endpoints (at 12 Months) and Major Secondary Endpoint (at 13 Months) Binary angiographic restenosis 2) Composite Safety MACE = All cause death, reinfarction, stent thrombosis (ARC definite or probable)**, or stroke 1) Ischemia-driven TLR* 11 * Related to randomized stent lesions (whether study or non study stents were implanted); ** In randomized stent lesions with ≥1 stent implanted (whether study or non study stents) Stone GW. TCT 2008.

Statistical Methodology ● Second randomization stratification i.Results from the first randomization ii.Presence of medically treated diabetes mellitus iii.Presence of any lesion >26 mm in length (requiring overlapping stents by protocol) iv.U.S. vs. non-U.S. site ● Primary analysis conducted in the ITT cohort using Kaplan- Meier methodology, with the groups compared by log-rank ● 1-sided α=0.025 for NI; 2-sided α=0.05 for Sup Stone GW. TCT 2008.

Power Analysis ● With 2,850 pts randomized 3:1* Assumed event rates One YearTestEXPRESSTAXUS  Power Ischemic TLRSuperiority9.0%5.0%-95% Composite Safety MACE Noninferiority7.5% 3.0%80% Assumed event rates 13 MonthsTest EXPRESS TAXUS  Power RestenosisSuperiority26.0%15.6%-96% ● With angiographic FU in 1,125 randomized pts (analyzable) * Assumed 5% withdrew or lost to FU at 1 year → 3000 randomized Stone GW. TCT 2008.

Horizons Enrollment - Centers ● 3,602 pts randomized at 123 centers in 11 countries between March 25th, 2005 and May 7th, 2007 USA (57) (1) Spain (6) UK (2) Norway (2) Norway Poland (9) Germany (16) Austria (5) (3) Netherlands Italy (2) Argentina (12) Israel (10) Stone GW. TCT 2008.

R 1:1 HORIZONS AMI Trial Design Harmonizing Outcomes with Revascularization and Stents in AMI UFH + GPI (n=1802) Bivalirudin (n=1800) Withdrew Withdrew Lost to FU Lost to FU pts with STEMI Randomized 1-Year FU TAXUS N=2257 N=2186 (96.9%) EXPRESS BMS N=749 N=715 (95.5%) R 3:1 Primary Medical Rx193 Primary CABG 62 Deferred PCI 2 Index PCI, not eligible - PTCA only119 - Stented pts eligible for stent rand. 93.1% of all stented pts were randomized Stone GW. TCT 2008.

Baseline Characteristics (i) TAXUS (N=2257) EXPRESS (N=749) Age (years)59.9 [52.4, 69.4]59.3 [51.8, 69.2] Male77.0%76.0% Diabetes16.1%15.2% Hypertension51.2%51.9% Hyperlipidemia42.2%41.1% Current smoking46.3%51.9% Prior MI9.1%10.9% Prior PCI9.5%7.7% Prior CABG2.2%1.9% *P=0.009 * Stone GW. TCT 2008.

Baseline Characteristics (ii) TAXUS (N=2257) EXPRESS (N=749) Weight (kg)80 [71, 90] Killip class %8.0% Anterior MI42.2%44.7% LVEF (%), site50 [44, 59]50 [43, 58] Symptoms – PCI, hrs3.7 [2.7, 5.5]3.8 [2.7, 5.8] Femoral a. access93.6%92.9% Venous access8.5%8.0% Closure device30.1%28.8% Aspiration catheter11.4%10.7% Stone GW. TCT 2008.

Study Drugs TAXUS (N=2257) EXPRESS (N=749) Aspirin at home22.7%20.5% Aspirin load pre PCI97.0%97.2% Thienopyridine at home2.1%2.5% Thienopyridine loading dose98.9%98.3% - clopidogrel 300 mg34.2%35.5% - clopidogrel 600 mg63.3%61.3% - clopidogrel other1.2%1.3% - ticlopidine0.5%0.3% UFH pre randomization65.2%65.8% UFH as the procedural antithrombin49.8%50.1% Bivalirudin administered50.7%50.9% GP IIb/IIIa inhibitor administered52.0%51.5% Stone GW. TCT 2008.

Procedural Data (Site Reported) TAXUS (N=2257, L=2495) EXPRESS (N=749, L=815) N lesions treated1.1 ± ≥ 2 lesions treated11.1%9.0% - ≥ 2 vessels treated4.5%3.1% Direct stenting attempted30.4%33.7% Stent target lesion: LAD, LCX, RCA, LM, SVG 40.1%, 14.6%, 45.1%, 0.3%, 0.3% 42.4%, 15.9%, 41.3%, 0.4%, 0.4% N stents implanted1.5 ± ± 0.7 Total stent length**30.8 ± ± 14.9 Max balloon dia. (mm)3.00 [2.75, 3.50]3.00 [2.90, 3.50] Max pressure (atm.)14.0 [12.0, 16.0] *P=0.002; **P< * ** Stone GW. TCT 2008.

Quantitative Coronary Angiography TAXUS (L=2642, V=2353) EXPRESS (L=857, V=771) Pre RVD (mm)2.89 ± ± 0.50 Pre MLD (mm)0.35 ± 0.45 Pre %DS87.6 ± ± 15.4 Pre lesion length (mm)17.5 ± ± 8.8 Pre TIMI 0/1, 2, 360.6%, 13.6%, 25.7%57.4%, 15.2%, 27.4% Post RVD (mm)2.93 ± ± 0.50 Post MLD (mm)*2.36 ± ± 0.52 Post %DS*19.9 ± ± 11.1 Acute gain (mm)**2.04 ± ± 0.62 Post TIMI 0/1, 2, 31.7%, 10.7%, 87.6%0.9%, 9.3%, 89.8% *Analysis segment, all lesions, whether stented or not; **stented lesions only; †P=0.006 † Stone GW. TCT 2008.

Aspirin and Thienopyridine Use Regular* aspirin use (%) Regular* thieno. use (%) *Taken >50% of days since last visit Antiplatelet agent use (%) P <0.001 Stone GW. TCT 2008.

Time in Months Primary Efficacy Endpoint: Ischemic TLR Ischemic TLR (%) Diff [95%CI] = -3.0% [-5.1, -0.9] HR [95%CI] = 0.59 [0.43, 0.83] P=.002 TAXUS DES (n=2257) EXPRESS BMS (n=749) % 4.5% Number at risk TAXUS DES EXPRESS BMS Stone GW. TCT 2008.

Time in Months Secondary Efficacy Endpoint: Ischemic TLR Ischemic TLR (%) Diff [95%CI] = -3.0% [-5.2, -0.7] HR [95%CI] = 0.65 [0.48, 0.89] P=.006 TAXUS DES (n=2257) EXPRESS BMS (n=749) % 5.8% Number at risk TAXUS DES EXPRESS BMS Stone GW. TCT 2008.

Time in Months Primary Safety Endpoint: Safety MACE* Safety MACE (%) Diff [95%CI] = 0.1% [-2.1, 2.4] HR [95%CI] = 1.02 [0.76, 1.36] P NI =0.01, P Sup =0.92 TAXUS DES (n=2257) EXPRESS BMS (n=749) % 8.0% Number at risk TAXUS DES EXPRESS BMS * Safety MACE = death, reinfarction, stroke, or stent thrombosis Stone GW. TCT 2008.

Time in Months One-Year All-Cause Mortality Mortality (%) HR [95%CI] = 0.99 [0.64,1.55] P=0.98 TAXUS DES (n=2257) EXPRESS BMS (n=749) % Number at risk TAXUS DES EXPRESS BMS Stone GW. TCT 2008.

Time in Months One-Year Death or Reinfarction Death or MI (%) HR [95%CI] = 0.97 [0.70,1.32] P=0.83 TAXUS DES (n=2257) EXPRESS BMS (n=749) 4 7.0% 6.8% Number at risk TAXUS DES EXPRESS BMS Stone GW. TCT 2008.

Time in Months Stent Thrombosis (ARC Definite or Probable) Stent Thrmobosis (%) HR [95%CI] = 0.92 [0.58,1.45] P=0.72 TAXUS DES (n=2238) EXPRESS BMS (n=744) 2 3.4% 3.1% Number at risk TAXUS DES EXPRESS BMS Stone GW. TCT 2008.

Stent Thrombosis Rates* TAXUS (N=2238) EXPRESS (N=744) Hazard ratio [95%CI] P Value Stent thrombosis, ≤30 days2.3%2.7%0.87 [0.52,1.46] ARC** definite1.9%2.3%0.83 [0.47,1.45] ARC probable0.5%0.4%1.11 [0.31,4.05]0.87 Stent thrombosis, >30d – 1y1.0%0.7%1.39 [0.52,3.68] ARC definite0.9%0.7%1.25 [0.47,3.35] ARC probable0.1%0%–0.42 Stent thrombosis, ≤1 year3.1%3.4%0.92 [0.58,1.45] ARC definite2.6%3.0%0.86 [0.53,1.41] ARC probable0.5%0.4%1.33 [0.38,4.73]0.65 *Kaplan-Meier estimates, **ARC= Academic Research Consortium Stone GW. TCT 2008.

One Year Composite Safety Endpoints* TAXUS (N=2257) EXPRESS (N=749) HR [95%CI]P Value Safety MACE**8.1%8.0%1.02 [0.76,1.36]0.92 Death, all-cause3.5% 0.99 [0.64,1.55] Cardiac2.4%2.7%0.90 [0.54,1.50] Non cardiac1.1%0.8%1.32 [0.54,3.22]0.55 Reinfarction3.7%4.5%0.81 [0.54,1.21] Q-wave2.0%1.9%1.07 [0.59,1.94] Non Q-wave1.8%2.7%0.68 [0.39,1.17]0.16 Stent thrombosis † 3.1%3.4%0.92 [0.58,1.45] ARC definite2.6%3.0%0.86 [0.53,1.41] ARC probable0.5%0.4%1.33 [0.38,4.73]0.65 Stroke1.0%0.7%1.52 [0.58,4.00]0.39 *Kaplan-Meier estimates; **Primary safety endpoint; †ARC (Academic Research Consortium) definite or probable Stone GW. TCT 2008.

Angiographic Follow-up TAXUS DES N=1348 EXPRESS BMS N=452 Randomized Eligible N=1308N= consecutive eligible pts assigned to 13 month angiographic FU* * Randomized in stent arm; stent procedure successful (DS <10%, TIMI-3 flow, ≤NHLBI type A peri-stent dissection); no stent thrombosis or CABG w/i 30 days 4011 Died before angio FU Died before angio FU N=942 (72.0%) N=307 (69.6%) Completed Angio FU Angio FU not performed Angio FU not performed Not received/analyzable Not received/analyzable Out of window Out of window N=911N=293 Analyzed Lesions Lesions Stone GW. TCT 2008.

Follow-up QCA TAXUS (L=1081, V=964) EXPRESS (L=332, V=302) P value TIMI flow - 0/12.8%3.6% %5.0% %91.4%0.55 FU RVD (mm)2.91 ± ± FU MLD in-stent (mm)2.36 ± ± 0.82< FU MLD in-segment (mm)2.08 ± ± 0.76< FU %DS in-stent18.8 ± ± 24.9< FU %DS in-segment28.8 ± ± 22.0< Aneurysm0.5%0.9%0.40 Ulcerated0.5%0.6%0.67 Ectasia0.7%0.9%0.73 Stone GW. TCT 2008.

Binary Analaysis Segment Restenosis at 13 Months ● Patient with Lesion Level Analysis* Binary Restenosis (%) 32 * ITT: Includes all stent randomized lesions, whether or not a stent was implanted, and whether or not non study stents were placed ** Any lesion with restenosis  per pt restenosis RR [95%CI] = 0.44 [0.33, 0.57] P < RR [95%CI] = 0.44 [0.33, 0.57] P < Major 2  endpoint Stone GW. TCT 2008.

Angiographic Late Loss at 13 Month ● Lesions with Stents Implanted P < P=0.07 Late loss (mean, mm) † 33 P=0.18 P < ± 0.42 ± 0.54 ± 0.64 ± 0.70 ± 0.56 ± 0.64 ± 0.47 ± 0.50 Stone GW. TCT 2008.

Binary Angiographic Restenosis at 13 Months ● Lesions with Stents Implanted † 34 Binary Restenosis (%) RR [95%CI] = 0.42 [0.32, 0.54] P < RR [95%CI] = 0.39 [0.29, 0.52] P < Stone GW. TCT P =0.13 P =0.42

Limitations ● Open label design –Potential bias was mitigated by high protocol procedure compliance and use of blinded clinical event adjudication committees and core laboratories ● Underpowered for stent thrombosis and death –The virtually identical rates of MACE in the TAXUS and EXPRESS groups makes it unlikely that major safety differences exist favoring either stent type at 1-year Stone GW. TCT 2008.

Conclusions ● In this large-scale, prospective, randomized trial of pts with STEMI undergoing primary stenting, the implantation of paclitaxel-eluting TAXUS stents compared to bare metal EXPRESS stents resulted in: –A significant 41% reduction in the 1-year primary efficacy endpoint of ischemia-driven TLR, and a significant 56% reduction in the 13 month major secondary efficacy endpoint of binary restenosis –Non inferior rates of the primary composite safety endpoint of all cause death, reinfarction, stent thrombosis or stroke at 1- year Stone GW. TCT 2008.

Conclusions ● The long-term safety and efficacy profile of paclitaxel-eluting TAXUS stents compared to bare metal EXPRESS stents in STEMI will be determined by the ongoing 5 year follow-up of patients randomized in the HORIZONS-AMI trial Stone GW. TCT 2008.